Клиника и терапия биполярной депрессии



страница4/4
Дата22.04.2016
Размер0.53 Mb.
1   2   3   4

8. Akiskal H.S., Pinto Q. The evolving bipolar spectrum prototypes I, II, III and IV. The Psychiatric clinics of North America. Bipolarity:Beyong classic mania, ed. H. Akiskal. Saunders Co. Philadelphia, 1999, Vol. 22, No. 3, Sept., P. 517-535.

9. Altshuler L.L., Post R.M., Levehch G.S., Mikalauskas K., Rosoff A., Ackerman L. Antidepressant-induced mania and cycle accel­eration: a controversy revisited //Am. J. Psychiatry. - 1995. 152 : 1130-1138.

10. Altshuler L, Kiriakos L, Calcagno J. et al. The impact of antide­pressant discontinuation versus antidepressant continuation on 1 -year risk for relapse of bipolar depression: a retrospective chart review//J. Clin. Psychiatry. - 2001. 62 : 612-616.

11. Altshuler L, Suppes Т., Black D. et al. Impact of antidepressant

discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up // Am. J. Psychiatry. -2003; 160:1252-1262.

12. Amsterdam J., Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression // J. Affect Disord. - 2005. 87: 121-130

13. Amsterdam J.D., Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive epi­sode: a randomized open-label study//J. Clin. Psychopharmacol. -2008. April, 28 (2):171-81.

14. Angst J. The course of affective disorders : II. Typology of bipolar manic-depressive illness // Archiv fur Psychiatrie und Nervenk-rankheiten, 1978, 226, 65-73.

15. A.P.A. Practice guideline forthenotreatment of patients with bipolar disorder (revision) //Am. J. Psychiatry. - 2002. 159: 1-50.

16. Baldessarini R.J. etal. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders // Psychiatr Serv. 2007, 58(1).

17. BallengerJ.C, PostR.M. Carbamazepine in manic-depressive ill­ness: A new treatment // Am. J. Psychiatry. - 1980. Vol. 137, P. 782-790.

18. BallengerJ.C. The clinical use of carbamazepine in affective dis­orders//J. Clin. Psychiatry. - 1988. 49 (Suppl.): 13-21.

19. Bebbington P., Ramana R. The epidemiology of bipolar affective disorder//Soc. Psychiatry Psychiatr. Epidemiol. - 1995. Vol. 30, P. 279-92.

20. Benazzi F. Prevalence of bipolarll disorder in outpatient depres­sion. A203-case study in private practice // J. Affect. Disord. -1997. Vol.43, P. 163-166.

21. Bowden C.L. Lamotrigine in the treatment of bipolar disorder // Expert Opin Pharmacother 2002, 3: 1513-19.

22. CalabreseJ.R., Deluccni G.A. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder//Am. J. Psychia­try. - 1990. Vol.147, P. 431-434.

23. CalabreseJ.R., Bowden C, FieveR. etal. Adouble-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression//J. Clin. Psychiatry. - 1999, 60:79-88.

24. Calabrese J. R., Macfadden W., McCoy R., Minkwitz M., Wilson E., Kuklen J. Double-blind placebo-controlled study of quetiapine in bipolar depression //АРА Annual Meeting, New YORK, Abstracts NR 2004.

25. Calabrese J.R., Keck P.E., Macfadden l/l/. et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treat­ment of bipolar I or II depression//Am. J. Psychiatry- 2005. 162: 1351-1360.

26. Cassano G.B., Akiskal H.S., Savino M. et al. Proposed Subtypes of bipolar 2 and related disorders:with hypomanic episodes (or cy­clothymia) and with hyperthymic temperament//J. Affect Disord. -1992. Vol.11, P. 205-206.

27. Cassano G.B., Jori M.C., and AMIMAJOR Group. Efficasy and safety of amisulpride 50 mg versus paroxetine 20 mg in major de­pression: A randomized, double-blind, parallel group study. Int Clin Psychopharmacol. - 2002. 17: 27-32. 284.

28. Catapano-Friedman L. Effectiveness of quetiapine in the manage­ment of psychotic depression in an adolescent boy with bipolar disorder, mixed, with psychosis//J. Child Adol Psychopharmacol. -2001;11:205-206.

29. Compton M.T., Nemeroff C.B. The treatment of bipolar depres­sion //J. Clin. Psychiatry. - 2000. Vol. 61, No. 9, P. 57-67.

30. Corapcioglu A., Kocabasoglu N., Yargic I. A randomized, single-blind, multicenter prospective trial comparing the efficasy and sefety of paroxetine with or wiyhout quetiapine therapy on depres­sion associated with anxiety. - 2003.

31. Coryell W., Scheftner W., Keller M. et al. The enduring psychoso­cial consequences of mania and depression // Am. J. Psychiatry. - 1993. Vol. 150, P. 720-727.

32. Coryoll W., EndicottJ., MaserJ.D. etal. Long term stability of po­larity distinctions in the affective disorders // Am. J. Psychiatry. -1995. Vol. 152,385-390.

33. Daly J.J., PmdicJ., Devanand D.P. etal. ЕСТ in bipolar and unipo­lar depression: differences in speed of response // Bipolar Disord. -2001. 3(2): 95-104.

34. Daws L.L., Bartolucci A., Petty F. Divalproex in the treatment of bi-

polar depression: a placebo-controlled study // J. Affect. Disord. - 2005.85(3):259-66.

35. DoreeJ.P, Tourjman V., Kunicki S., Desrosiers J'., Vanise C, Elie R., Lew V.A. Comparison of quetiaoine versus lithium treatment resistant depression. АРА Annual Meeting, New YORK, Abstracts NR. - 2004, 273.

36. Ehnvall A., Agren H. Patterns of sensitization in the course of af­fective illness / A life-charting study of treatment-refractory de­pressed patients//J. Affect. Disord. - 2002. Vol.70, P. 67-75.

37. Fountouiakis K.N., Vieta E., Sanchez-Moreno J. et al. Treatment guidelines for bipolar disorder: a critical review //J. Affect Disord. -2005.86(1): 1-10.

38. Frye M., Ketter T.A., Kimbrell T.A. etal. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders//J. Clin. Psychopharmacol. 2000. 20 : 607-614.

39. Gao K, Gajwani P., Elhaj O., Calabrese J.R. Typical and atypical antipsychotics in bipolar depression //J. Clin. Psychiatry. - 2005. Nov., 66 (11): 1376-1385.

40. Gelenberg A.J., Kane J.M., Keller M.B. Comparison of standart and low serum levels of lithium for maintance treatment of bipolar disorders//N. Engl. J. Med. - 1989. P. 1489-1493.

41. Gijsman H. J. etal. Antidepressants for Bipolar Depression: A Sys­tematic Review of Randomized, Controlled Trials//Am. J. Psychi­atry. - 2004. 161 :1537-1547.

42. Goodwin F.K., Jamison К Manic-Depressive Illness. - New York: Oxford University Press, 1990.

43. Goldberg J. Spontaneons depression versus biphasic cycling // Am. J. Psychiatry.-2001. Vol.158, P. 124-126.

44. Grunze et al. World Federation of Societies of Biological Psychia­try Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression //World J. Biol. Psychiatry. -(2002)3, 115-124.

45. Handtouch E. G, Akiskal H. S., Lancrenon S. et al. Systematic clini­cal methodology for validating bipolar II disorder//J. Affect. Dis­ord. -1998. Vol. 50, P. 163-173.

46. Hirschfeld R.M.A., Lewis L., VornikL.A. Perceptions and impact of bipolar disorder: How far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder // J. Clin. Psychiatry. - 2003. 64: 161-74.

47. JuddL.L., AkiskalH.S., SchettlerP.J., EndicottJ., MaserJ., Solo­mon D.A., LeonA.C, Rice J.A., Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder // Arch. Gen. Psychiatry. - 2002, Jun. No. 59 (6), P. 530-537.

48. Kalinin V.V. Suicidally and Antiepileptic Drugs: Is there a Link? Drug Saf. - 2007. 30 (2) : 123-42.

49. Keck RE., McElroy S.L. Divalproex in the Treatmentof Bipolar Disor­der// Psychopharmacology. - Bulletin 2003. 37 (Suppl. 2): 67-73.

50. Keller M.B., Lavori P.W., Coryell W. etal. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness // JAMA. - 1986. Vol. 255, P. 3138-3142.

51. Ketter T.A., Calabrese J.R. Stabilization of mood from below ver­sus above baseline in bipolar disorder: a new nomenclature // J. Clin. Psychiatry. - 2002. 63 : 146-151.

52. Kravitz H.M., Fawcett J. Carbamazepine in the treatment of affec­tive disorders//Med. Sci. Res. - 1987, No. 15, P. 1-8.

53. Kupfer D.J., Frank E., Grochocinski V.J. et al. Stabilization in the treatment of mania, depression and mixed states // Acta Neu­ropsychiatries. - 2000. No. 12, P. 110-114.

54. Lambert P.A. Acute and prophylactic therapies of patients with affective disorders using valpromide (dypropylaetamide). In: An­ticonvulsants in affective disorders Edited by H.E. Emrich, T Oku-ma, A.A .Muller. Elsevier Science Publishers. - Amsterdam, Ox-ford, Princeton, 1984.

55. Lish J.D., Dime-Meenan S., WhybrowRC. etal. The national De-piessivo and Manic-Depressive Association (DMDA) survey of bi-polai members// J. Affect. Disord. - 1994. Vol. 31, No. 4, P. 281-;"M

56. Mnclnddon W., Calabrese J., McCoy R., Minkwitz R., Wilson £., Mullen J. Double-blind, placebo-controlled study of quetiapine In bipolar I depression. Poster presented at the XXIVth Collegium Internationale Nouro-Psychopharmacologicum (CINP) Congress, June 20-24, 2004, Paris, France.

57. Malhi G.S., Vieta E. Topics in contemporary psychiatric practice diagnosing bipolar disorder // Int. J. Psych. Clin. Pract. - 2001. Vol. 5, No. 3, P. 223-224.

58. Malhi G.S., Mitchell P.В., Salim S. Bipolar depression: manage­ment options // CNS Drugs. - 2003. 17(1): 9-25.

59. Mclntyre R.S., Mancini D.A., McCann S. etal. Topiramate versus bupropion SR when added to mood-stabilizer therapy for the de­pressive phase of bipolar disorder: a preliminary single-blind study // Bipolar Disord., 2002, Vol. 4, No. 3, P. 207-213.

60. Medical Practice Project. A state-of-the-science report for office of Assistant Secretary for the US Department of Health, Education Welfare. - Baltimore, 1979.

61. Miller-Siecheneder F., Miller M.J., Hillert A., Szegedu A., Wetzel H., Benkert O. Risperidone versus haloperidol in the treatment of patients with a combined psychotic and depressive syndrome //J. Clin. Psychopharmacol.-1998. 18: 111-120.

62. Montgomery S.A. The advantages of paroxetine in different sub­groups of depression // Int. Clin. Psychopharmacol. - 1992. Vol. 6, (suppl 4), P. 91-100.

63. Mitchell P.B., Wilhelm K, Parker G. et al. The clinical featuresof bipolar depression: a comparison with matched major depressive disorder patients // J. Clin. Psychiatry. - 2001. P. 62.

64. Mitchell P. В., BallJ.R., Best J. A. etal. The management of bipolar disorder in general practice // MJA. - 2006. 184 (11): 566-70.

65. Nemeroff С et al. Pharmacotherary of depression and mixed states in bipolar disorder // J. Affect. Disord. - 2000. Sept., V. 59, Suppl. 1, P. 39-56.

66. Nemeroff С. В. etal. Double-blind, placebo-controlled compari­son of imipramine and paroxetine in the treatment of bipolar de­pression//Am. J. Psychiatry. - (2001) 158 : 906-912.

67. Neumann J., Siedel K., Wunderlich H. Anticonvulsants in affective disorders/Ed. byH.M. Emrich etal. Amsterdam Oxford Princeton: Exerpta Medica, 1984. P. 1160-1166.

68. Perris С A study of bipolar (manic-depressive) and unipolar recur­rent depressive psychoses // Acta. Psychiatr. Scand. - 1966. Vol. 42, P. 1-188.

69. PostR.M. Transduction of psychological stress into the neurobiology of recurrent affective disorder // Am. J. Psychiatry. - 1992. Vol.149, P. 999-1010.

70. Posf P.M. etal. Alternative approaches to refractory depression in bipolar illness //Depress Anxiety. - 1997. 5 : 175-189.

71. Post P.M., Unde T.W., Poy-Byrne P.P. etal. Antidepressant effects of carbamazepine//Am. J. Psychiatry. - 1986. 143 : 29-34.

72. Post R. M., Denicoff K. D., Leverich G. S., Altshuler L. L et al. Pres­entation of depression in bipolar illness. Clinical neuroscience Re­search 2. - 2002. P. 142-157.

73. Post P.M., Leverich G.R., Nolen W.A. et al. A reevaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network // CNS Spec­trum, 2003. Vol. 8, No. 12 (Suppl. 4), P. 1-15.

74. Post R.M. Recent data from the Stanley Foundation bipolar treat­ment outcome network // CNS Spectrum. - 2004. Vol. 9, No.1 (Suppl. 1). P. 1-24.

75. Post R.M., Altshuler L.L., Leverich G.S., Frye M.A., Nolen W.A., Kupka R.W., Suppes T, McElroy S., Keck P.E., Denicoff K.D., Grunze H., Walden J., Kitchen CM., MintzJ. Mood switch in bipo­lar depression: comparison of adjunctive venlafaxine, bupropion and sertraline//Br. J. Psychiatry. -2006. Aug., 189: 124-31.

76. Prien R.F., Klett C.J., Caffey E.M. Lithium carbonate and imi-pramine in the prevention of affective episodes //Arch. Gen. Psy­chiatry. - 1973. Vol. 29, P. 420-425.

77. Prudic J., Sackeim H., Devanand D.P Medication resistance and clinical response to ЕСТ//Psychiatry Res. - 1990. 31 : 287-96.

78. RapaportM.N., Canuso CM., Rouillon F., LeblancJ., Young A.H., Loosher A., Bossie C, Turkoz I., Gharabawi G. Results from the augmentation with risperidone in resistant depression trial //АРА Annual Meeting, New York, Abstracts NR. - 2004. 301 p.

79. Roy-Byme P., Post R.M., Uhde T.W. etal. The longitudinal course ol mcuimnl affective illness: life chart data from research patients al Hi.; NIMH//Acta. Psychiatr. Scand. - 1985. Vol. 317, P. 1-34.

80. Sachs G.S., Later В., Stoll A.L., Banou M., Triboult A.B., Tohen M., Honcnhntim J.F. A double-blind trial of bupropion versus desipramine for bipolar depression // J. Clin. Psychiatry. - 1994. Vol. 55, P. 391-393.

81. Sachs G.S., Ghaemi S.N. Safety and efficacy of risperidone ver­sus placebo in combination with lithium or valproate in the treat­ment phase of bipolar disorder // Int. J. Neuropsychopharmacol. -2000, 3 (suppl. 1):S. 143, (Abstract).

82. Sachs G.S., Altshuler L.L., Ketter T.A. etal. Divalproex versus pla­cebo for the treatment of bipolar depression // American College of Neuropsychopharmacology. Abstracts. 2001.

83. Sachs G.S. STEP-BD Update: What have we learned, in Interna­tional Bipolar Disorder. - 2003. Pittsburgh, PA: Western Psychiat­ric Institute and Clinic, UPMC Health System.

84. Sachs G. Managing bipolar affective disorder. - London, Science Press.-2004. 146 p.

85. Sachs G. Antidepressants may be useless in bipolar depression. 21st ECNP Congress, Barselona, Spain, 30 Aug.-3 Sept., 2008.

86. Small J.G. Anticonvulsants in affective disorders // Psychophar-macol Bull. - 1990. 26 : 25-36.

87. Stahl S.M., Shelton R.C. Risperidone with and without par­oxetine compared to paroxetine alone for bipolar depression // ACNP Annual Meeting, Waikoloa, Hawaii, Abstracts. 2001, 352 p.

88. Stromgren L., Bolloi S. Carbamazepine in treatment and prophy­laxis of manic-depressive disorder// Psychiat. Dev. - 1985. Vol. 4, P. 349-367.

89. Suppes Т., Kelly D.I., Perla J.M. Challenges in the management of bipolar depression // J. Clin. Psychiatry. - 2005. 66 (Suppl. 5): 11-16.

90. The Expert Consensus Guideline Series. Treatment of bipolar dis­order. Steering Committee: Allen Frances, John P. Docherty, David A. Kahn // The Journal of Clinical Psychiatry. - 1996. V 57, Sup­pl. 12A.

91. Tohen M., Vieta E., Calabiose J.R. etal. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar de­pression. Arch. Gen. Psychiatry. - 2003. 60: 1079-1088.

92. Tondo L., Baldessarini R.J., Floris G. Long-term clinical effec­tiveness of lithium maintenance treatment in types I u II bipolar disorders // Brit. J. Psychiatry. - 2001. Vol. 178. (Suppl.41), P. 184-190.

93. Tondo L, Baldessarini R.J. Rapid cycling in women and men with bipolar manic-depressive disorders//Am. J. Psychiatry. - 1998. 155:1434-1436.

94. Truman E.etal. Retrospective review of the bipolar disorder course in community // Poster at АРА annual meeting San Francisco, May 17-22, 2003. Abstract 251.

95. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy// N. Engl. J. Med. - 2008. 358 : 252-260.

96. Vieta E. Managing Bipolar Disorder in Clinical Practice // Published by Current medicine group Ltd, Porters South, London, UK, 2006.

97. Wehr ТА., Goodwin F.K. Can antidepressants cause mania and worsen the course of affective illness?//Am. J. Psychiatry*) 1987. Vol. 144, P. 1403-1411.

98. Weisler R. H., Calabrese J. R., Thase M. E., Arvekvist R., Stening G., Paulsson В., Suppes T. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies.

99. Westenberg H.G.M., Denis D., Klompmakers A.A. Synergistic ef­fects of quetiapine in combination with fluvoxamine on dophamine release in rat prefrontal cortex (abstract) // Eur. Neuropsychop-harmacology. - 2003. Vol. 3, (Suppl.4), P. 462.

100. Winsberg M.E., DeGolia S.G., Strong C.M. etal. Divalproex ther­apy in medication-naive and mood-stabilizer-naive bipolar II de­pression // J. Affect. Disord.- 2001. 67 (1 -3): 207-212.

101. Zomberg G.L., Pope H.G. Treatment of depression in bipolar disorder: new directions for research // J. Clin. Psychopharmacol. -1993. Vol. 13, P. 397-408.

_________________________________________________________________________________________

C.H. Мосолов, Е.Г. Костюкова, А.В. Ушкалова Клиника и терапия биполярной депрессии

ООО «AMА-ПРЕСС», 1111 16,1. Москва, Энергетический пр., д. 3, стр.1





1   2   3   4


База данных защищена авторским правом ©bezogr.ru 2016
обратиться к администрации

    Главная страница